Kirin Brewery Co., Ltd. Introduces Pneumococcal Antigens From Intercell AG, Accelerates Research On Antibody Drug Development

Published: Apr 13, 2006

Tokyo, Apr 11, 2006 (JCN) - Kirin Brewery and Intercell AG have entered into a strategic alliance whereby Kirin will receive the worldwide exclusive rights to develop, manufacture and sell pneumococcal antigens identified by Intercell, a Vienna-based company specializing in vaccines development.

Back to news